Negredo Eugènia, Clotet Bonaventura, Puig Jordi, Pérez-Alvarez Núria, Ruiz Lidia, Romeu Joan, Moltó José, Rey-Joly Celestino, Blanco Julià
Lluita contra la SIDA, Germans Trias i Pujol University Hospital, Universitat Autònoma de Barcelona, Badalona, Barcelona, Spain.
AIDS. 2006 Feb 28;20(4):619-21. doi: 10.1097/01.aids.0000210617.90954.0e.
We conducted a pilot study to assess the effect of atorvastatin on HIV replication. Patients with stable HAART-controlled infection interrupted therapy and were randomly assigned to a control group or to start atorvastatin 40 or 80 mg/day. Statin groups showed lower serum cholesterol but similar viral loads and CD4 T-cell counts to the control group at weeks 4 and 12. Paradoxically, baseline serum cholesterol, but not atorvastatin, influenced viral rebound at week 4.
我们进行了一项初步研究,以评估阿托伐他汀对HIV复制的影响。接受高效抗逆转录病毒治疗(HAART)且感染病情稳定的患者中断治疗,并被随机分配至对照组,或开始每日服用40毫克或80毫克阿托伐他汀。在第4周和第12周时,他汀类药物组的血清胆固醇水平较低,但病毒载量和CD4 T细胞计数与对照组相似。矛盾的是,第4周时的病毒反弹受基线血清胆固醇的影响,而非阿托伐他汀的影响。